Charline Caumont

Dr. Charline Caumont

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
EBEtienne Buscail
Etienne Buscail
Catherine Alix-PanabieresCatherine Alix-Panabieres
Catherine Alix-Panabieres
PQPascaline Quincy
Pascaline Quincy
TCThomas Cauvin
Thomas Cauvin
ACAlexandre Chauvet
Alexandre Chauvet
LCLaurence Chiche
Laurence Chiche
Purpose: Expediting the diagnosis of pancreatic ductal adenocarcinoma (PDAC) would benefit care management, especially for the start of treatments requiring histological evidence. This study evaluated the combined diagnostic performance of circulating biomarkers obtained by peripheral and portal blood liquid biopsy in patients with resectable PDAC. Experimental design: Liquid biopsies were performed in a prospective translational clinical trial (PANC-CTC #NCT03032913) including 22 patients with resectable PDAC and 28 noncancer controls from February to November 2017. Circulating tumor cells (CTCs) were detected using the CellSearch® method or after RosetteSep® enrichment combined with CRISPR/Cas9-improved KRAS mutant alleles quantification by droplet digital PCR. CD63 bead-coupled Glypican-1 (GPC1)-positive exosomes were quantified by flow cytometry. Results: Liquid biopsies were positive in 7/22 (32%), 13/22 (59%), and 14/22 (64%) patients with CellSearch® or RosetteSep®-based CTC detection or GPC1-positive exosomes, respectively, in peripheral and/or portal blood. Liquid biopsy performance was improved in portal blood only with CellSearch®, reaching 45% of PDAC identification (5/11) versus 10% (2/22) in peripheral blood. Importantly, combining CTC and GPC1-positive-exosome detection displayed 100% of sensitivity and 80% of specificity, with a negative predictive value of 100%. High levels of GPC1+-exosomes and/or CTC presence were significantly correlated with progression-free survival and with overall survival when CTC clusters were found. Conclusion: This study is the first to evaluate combined CTC and exosome detection to diagnose resectable pancreatic cancers. Liquid biopsy combining several biomarkers could provide a rapid, reliable, noninvasive decision-making tool in early, potentially curable pancreatic cancer. Moreover, the prognostic value could select patients eligible for neoadjuvant treatment before surgery. This exploratory study deserves further validation.

16 December 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
LDLéa Dousset
Léa Dousset
FPFlorence Poizeau
Florence Poizeau
Caroline RobertCaroline Robert
Caroline Robert
SMSandrine Mansard
Sandrine Mansard
LMLaurent Mortier
Laurent Mortier
LBLise Boussemart
Lise Boussemart
PURPOSE: Emerging evidence suggests a correlation between the tumor mutational burden (TMB) and the response to programmed cell death-1 protein (PD-1) monotherapy across multiple cancer types. In skin cancers, as high TMB is mostly because of ultraviolet (UV) exposure, we hypothesized a correlation between the primary melanoma cutaneous location according to sun exposure and response to anti–PD-1 monotherapy.METHODS: The aim of this study was to analyze, in advanced melanoma, the relationship between TMB, locations according to sun exposure, and response to PD-1 inhibitors. We conducted a prospective multicentric analysis, by sequencing the most recent metastatic sample before PD-1 inhibitors using FoundationOne assay.RESULTS: One hundred two patients were included, with TMB available for 94 cases. In univariate and multivariate linear regression, TMB was significantly associated with sun-exposed areas of the primary melanoma location and with age (coefficients of the association with log-TMB: non-UV location, –1.05; chronic sun-exposed area, 1.12; P value for the location, < 10–5; age, 0.021 per year, P value for age, .002). Molecular UV signature present on the metastatic site was associated with higher TMB ( P = .003). Melanomas bearing a high TMB had a higher probability of response to PD-1 inhibitors compared with melanomas with a low TMB, with a dose-dependent effect following an exponential curve and a negative odds ratio of 0.40 (95% CI, 0.20 to 0.72, P = .004) between log-TMB and 6-month progression.CONCLUSION: Cumulative sun exposure related to skin location and molecular UV signature present on the metastatic site appear to be relevant biomarkers directly linked to TMB. Because TMB is not yet available to all for routine clinical use, the location of the primary melanoma in a sun-exposed area may play an important role in clinical decisions regarding therapeutic choice.

1 February 2016 in Lung Cancer
Verified
Journal Article
Closed access
CCCharline Caumont
Charline Caumont
RVRémi Veillon
Rémi Veillon
AGAudrey Gros
Audrey Gros
ELElodie Laharanne
Elodie Laharanne
HBHugues Bégueret
Hugues Bégueret
JMJean-Philippe Merlio
Jean-Philippe Merlio


4 December 2024 in Histopathology
Verified
Journal Article
Open access
FBFanny Beltzung
Fanny Beltzung
Marie BEYLOT-BARRYMarie BEYLOT-BARRY
Marie BEYLOT-BARRY
Maxime BattistellaMaxime Battistella
Maxime Battistella
CRCaroline Ram‐Wolff
Caroline Ram‐Wolff
AMAdèle De Masson
Adèle De Masson
BVBéatrice Vergier
Béatrice Vergier
Aims: Primary cutaneous marginal zone lymphoma (PCMZL) is considered a lymphoproliferative disorder (International Consensus Classification, ICC) or an overt lymphoma (WHO‐HAEM5). Seeking evidence for a reactive process or true lymphoma, we retrieved recurrent PCMZLs from the French Study Group of Cutaneous Lymphoma (GFELC) database.Methods: Histology, phenotype (light‐chain restriction, immunoglobulin, and immune‐receptor translocation‐associated protein‐1 [IRTA1] expression) and B‐cell clonality at diagnosis and recurrence were compared according to recurrence site (local, locoregional, or distant) and outcomes.Results: Initial lesions of the 61 patients (mean age 52) were mostly isolated on the trunk (48%) and classified T1 (70%). Times to first recurrence for local, locoregional, and distant recurrences, were 20, 29, and 37 months, respectively. Light‐chain restriction type did not differ significantly between local/locoregional recurrences and distal recurrences (P = 0.06; n = 60). The same B‐cell clones were identified for 23/42 local/locoregional recurrences, while 5/19 distant recurrences showed different clonal profiles (P = 0.0003). No tumour expressed IRTA1. Fifty‐eight tumours were heavy‐chain (IgG/IgG4) class‐switched PCMZLs and 3 IgM+/IgD– PCMZLs. All IgM+ tumours underwent either transformation (skin or brain) into diffuse large B‐cell lymphomas (DLBCLs) and extracutaneous spreading.Conclusion: As suggested by WHO‐HAEM5, immunoglobulin phenotype assessment (IgM alongside IgD) appears to be a possible valuable tool in the initial diagnosis of PCMZL to differentiate between the indolent class‐switched PCMZL (IgM‐negative) and IgM+ (IgD–) PCMZL, which has an uncertain prognosis. The variation in B‐cell rearrangements and light chain restriction observed in distant recurrences of PCMZL may suggest different antigen‐driven stimulation processes.

15 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CBClara Bastard
Clara Bastard
CCCharline Caumont
Charline Caumont
LSLaura Samaison
Laura Samaison
IQIsabelle Quintin-Roué
Isabelle Quintin-Roué
LDLaurent Doucet
Laurent Doucet
AUArnaud Uguen
Arnaud Uguen
Some pancreatic ductal-type (PDADK) and lung adenocarcinomas (LADK) lacking other molecular drivers are reported to harbor NRG1 fusions as potential novel therapeutic targets. We investigated the feasibility of a fluorescent in situ hybridization (FISH)-based diagnosis of NRG1 fusions in a case series of PDADK and LADK lacking other identified oncogenic drivers. First, among a case series of PDADK, KRAS analyses (PCR followed in PCR-negative cases by RNA sequencing—RNAseq) found 27/162 (16.7%) KRAS wild-type cases, among which 1/162 (0.6%) NRG1 fusion was diagnosed using FISH. Secondly, among a case series of LDAK, 191/446 (42.8%) cases had no molecular alterations in EGFR, KRAS, BRAF, HER2, MET, ALK, ROS1 and RET according to NGS and FISH analyses and, among them, 4/446 (0.9%) cases had NRG1 fusions using FISH. Finally, four additional cases out of the two previously mentioned cases series (1 PDADK and 3 LADK) with NRG1 fusions diagnosed by first-line RNAseq were also concluded as NRG1 FISH-positive. The NRG1 FISH tests for the nine NRG1 FISH-positive cases resulted in 50% to 80% of positive tumor nuclei, all with single 3′-NRG1 FISH signals. In our series, of the 22 cases analyzed with both NRG1 FISH (positivity criterion of at least 15% of tumor nuclei with a split between the 5′- and the 3′- parts of the probes and/or isolated single 3′-NRG1 signal) and RNAseq, 17 cases were FISH– RNAseq– and 5 cases were FISH+ RNAseq+ (no FISH+ RNAseq– or FISH– RNAseq+ cases in our study) resulting in 100% sensibility and specificity for the NRG1 FISH test. In the case of no access to RNAseq, NRG1 FISH consists of a valuable tool searching for NRG1 fusions in patients with advanced cancers.